350 related articles for article (PubMed ID: 34760723)
21. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne
Shields RK; Chen L; Cheng S; Chavda KD; Press EG; Snyder A; Pandey R; Doi Y; Kreiswirth BN; Nguyen MH; Clancy CJ
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031201
[TBL] [Abstract][Full Text] [Related]
22. A novel KPC-166 in ceftazidime/avibactam resistant ST307 Klebsiella pneumoniae causing an outbreak in intensive care COVID Unit, Italy.
Piazza A; Mattioni Marchetti V; Bielli A; Biffignandi GB; Piscopiello F; Giudici R; Tartaglione L; Merli M; Vismara C; Migliavacca R
J Microbiol Immunol Infect; 2024 Jun; 57(3):457-469. PubMed ID: 38584042
[TBL] [Abstract][Full Text] [Related]
23. Clinical and Molecular Epidemiologic Characteristics of Ceftazidime/Avibactam-Resistant Carbapenem-Resistant
Zhou J; Yang J; Hu F; Gao K; Sun J; Yang J
Infect Drug Resist; 2020; 13():2571-2578. PubMed ID: 32801794
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Two Distinct Subpopulations of Klebsiella pneumoniae ST16 Co-Occurring in a Single Patient.
Zhang B; Hu R; Liang Q; Liang S; Li Q; Bai J; Ding M; Zhang F; Zhou Y
Microbiol Spectr; 2022 Jun; 10(3):e0262421. PubMed ID: 35467408
[TBL] [Abstract][Full Text] [Related]
25. Combined effect of Polymyxin B and Tigecycline to overcome Heteroresistance in Carbapenem-Resistant Klebsiella pneumoniae.
Tian Y; Zhang Q; Wen L; Chen J
Microbiol Spectr; 2021 Oct; 9(2):e0015221. PubMed ID: 34704782
[TBL] [Abstract][Full Text] [Related]
26. In vivo selection of KPC-94 and KPC-95 in Klebsiella pneumoniae isolates from patients treated with ceftazidime/avibactam.
Guzmán-Puche J; Pérez-Nadales E; Pérez-Vázquez M; Causse M; Gracia-Ahufinger I; Mendez-Natera A; Allalou-Ruiz Y; Elías C; Oteo-Iglesias J; Torre-Cisneros J; Martínez-Martínez L
Int J Antimicrob Agents; 2022 Feb; 59(2):106524. PubMed ID: 35038557
[TBL] [Abstract][Full Text] [Related]
27. Effect of ramR loss-of-function insertion on tigecycline resistance in clinical isolates of carbapenem-resistant Klebsiella pneumoniae.
Mao Y; Shi Q; Zhang P; Jiang Y; Yu Y
J Glob Antimicrob Resist; 2020 Jun; 21():410-413. PubMed ID: 32006749
[TBL] [Abstract][Full Text] [Related]
28. Emergence of a KPC Variant Conferring Resistance to Ceftazidime-Avibactam in a Widespread ST11 Carbapenem-Resistant
Li X; Quan J; Ke H; Wu W; Feng Y; Yu Y; Jiang Y
Front Microbiol; 2021; 12():724272. PubMed ID: 34484166
[TBL] [Abstract][Full Text] [Related]
29. Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region.
Johnston BD; Thuras P; Porter SB; Anacker M; VonBank B; Snippes Vagnone P; Witwer M; Castanheira M; Johnson JR
Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32718965
[TBL] [Abstract][Full Text] [Related]
30. KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam.
Di Pilato V; Aiezza N; Viaggi V; Antonelli A; Principe L; Giani T; Luzzaro F; Rossolini GM
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33106265
[TBL] [Abstract][Full Text] [Related]
31. Tigecycline in combination with other antibiotics against clinical isolates of carbapenem-resistant Klebsiella pneumoniae in vitro.
Zhang J; Yu L; Fu Y; Zhao Y; Wang Y; Zhao J; Guo Y; Li C; Zhang X
Ann Palliat Med; 2019 Nov; 8(5):622-631. PubMed ID: 31735038
[TBL] [Abstract][Full Text] [Related]
32. Characteristic of KPC-12, a KPC Variant Conferring Resistance to Ceftazidime-Avibactam in the Carbapenem-Resistant
Han W; Zhou P; Chen C; Wu C; Shen L; Wan C; Xiao Y; Zhang J; Wang B; Shi J; Yuan X; Gao H; Wang H; Zhou Y; Yu F
Infect Drug Resist; 2024; 17():2541-2554. PubMed ID: 38933778
[TBL] [Abstract][Full Text] [Related]
33. Resistance evolution of hypervirulent carbapenem-resistant
Jin X; Chen Q; Shen F; Jiang Y; Wu X; Hua X; Fu Y; Yu Y
Emerg Microbes Infect; 2021 Dec; 10(1):1129-1136. PubMed ID: 34074225
[TBL] [Abstract][Full Text] [Related]
34. In vitro mimicry of in vivo KPC mutations by ceftazidime-avibactam: phenotypes, mechanisms, genetic structure and kinetics of enzymatic hydrolysis.
Shen S; Tang C; Yang W; Ding L; Han R; Shi Q; Guo Y; Yin D; Hu F
Emerg Microbes Infect; 2024 Dec; 13(1):2356146. PubMed ID: 38743401
[TBL] [Abstract][Full Text] [Related]
35. Ceftazidime-Avibactam Resistance in
Li D; Li K; Dong H; Ren D; Gong D; Jiang F; Shi C; Li J; Zhang Q; Yan W; Li Y
Infect Drug Resist; 2021; 14():1725-1731. PubMed ID: 34007191
[TBL] [Abstract][Full Text] [Related]
36. High ceftazidime-avibactam resistance among carbapenem-resistant Enterobacter species: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2014-2021.
Wang JL; Lai CC; Tsai YW; Ko WC; Hsueh PR
Int J Antimicrob Agents; 2024 Apr; 63(4):107105. PubMed ID: 38325719
[TBL] [Abstract][Full Text] [Related]
37. Clinical carbapenem-resistant
Shahid M; Ahmad N; Saeed NK; Shadab M; Joji RM; Al-Mahmeed A; Bindayna KM; Tabbara KS; Dar FK
Front Cell Infect Microbiol; 2022; 12():1033305. PubMed ID: 36304935
[TBL] [Abstract][Full Text] [Related]
38.
Yu F; Lv J; Niu S; Du H; Tang YW; Bonomo RA; Kreiswirth BN; Chen L
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891605
[TBL] [Abstract][Full Text] [Related]
39. Risk factors for and clinical outcomes of ceftazidime-avibactam-resistant carbapenem-resistant Klebsiella pneumoniae nosocomial infections: a single-center retrospective study.
Liu X; Chu Y; Yue H; Huang X; Zhou G
Infection; 2022 Oct; 50(5):1147-1154. PubMed ID: 35182356
[TBL] [Abstract][Full Text] [Related]
40. Molecular Epidemiology and Drug Resistant Mechanism of Carbapenem-Resistant
Shao C; Wang W; Liu S; Zhang Z; Jiang M; Zhang F
Front Public Health; 2021; 9():669173. PubMed ID: 34095072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
